Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study - Stintzing, S; Miller-Phillips, L; Modest, DP (Eur J Cancer, 2017)
et al.